PROCEPT BioRobotics Corp. to Present at the Virtual Key Bank Life Sciences & MedTech Investor Forum

Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a leader in surgical robotics focused on urology, announced management will present at the Virtual Key Bank Life Sciences & MedTech Investor Forum on March 21, 2023, at 12:45 p.m. Eastern Time. A live webcast will be available, with an archived recording for replay for 90 days. PROCEPT is renowned for its AquaBeam Robotic System, designed for minimally invasive urologic surgery, specifically targeting benign prostatic hyperplasia (BPH), which affects 40 million men in the U.S. The company boasts extensive clinical evidence supporting its Aquablation therapy.

REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- PROCEPT^® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming Virtual Key Bank Life Sciences & MedTech Investor Forum. Management is scheduled to present on Tuesday, March 21 at 12:45 p.m. Eastern Time. A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Matt Bacso, CFA
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com

FAQ

When is PROCEPT BioRobotics presenting at the Key Bank Investor Forum?

PROCEPT BioRobotics will present on March 21, 2023, at 12:45 p.m. Eastern Time.

Where can I watch the PROCEPT BioRobotics presentation?

The presentation will be available via live webcast on the investor section of PROCEPT BioRobotics' website.

What is the focus of PROCEPT BioRobotics?

PROCEPT BioRobotics focuses on developing surgical robotics solutions for urology, particularly for treating benign prostatic hyperplasia (BPH).

What is Aquablation therapy?

Aquablation therapy is designed to deliver effective treatment for lower urinary tract symptoms caused by BPH, independent of prostate size and surgeon experience.

How many clinical studies support Aquablation therapy?

Aquablation therapy is supported by a growing body of clinical evidence, including nine clinical studies and over 150 peer-reviewed publications.